For example, data have shown that rapamycin and everolimus can enhance the anti-tumour activity of paclitaxel (O'Reilly et al, 2003; Mondesire et al, 2004; Faried et al, 2006; Aissat et al, 2007; Haritunians et al, 2007) in a manner related in occurrence and extent to the tumour, dose, and interestingly, the sequence of administration of the mTOR inhibitor and paclitaxel (O'Reilly et al, 2003; Mondesire et al, 2004; Faried et al, 2006; Aissat et al, 2007). This evidence concerns the gene MTOR and neoplasm.